Dr Ailye Sevdem Gulcan’s (Bezmialem Vakif University, Turkey) poster presented the results of a single-centre, cross-sectional study that followed 43 patients with a diagnosis of chronic spontaneous urticaria [1]. On account of the COVID-19 pandemic, 15 of the patients (34.9%) discontinued their omalizumab injections. All 43 patients were interviewed by phone and completed the UAS and UCT questionnaires; these results were then compared with previous UAS and UCT scores in their files.
In patients who had discontinued omalizumab, there was a statistically significant increase in their UAS scores and a statistically significant decrease in their UCT scores. Among the patients who had kept up their omalizumab treatment regimen, neither their UAS nor their UCT scores were significantly different.
The team concludes that the COVID-19 pandemic has had a negative impact on the management of CSU in patients who discontinued their treatment protocol due to the pandemic.
- Gulcan S. Impact of COVID-19 Pandemic on Chronic Spontaneous urticaria: A Cross-sectional study from Turkey. P1616, EADV Virtual Congres, 29-31 October 2020.
Posted on
Previous Article
« Impact of personal protective equipment on acne vulgaris and rosacea Next Article
Low early PASI response could predict favourable outcomes for psoriasis patients on biologics »
« Impact of personal protective equipment on acne vulgaris and rosacea Next Article
Low early PASI response could predict favourable outcomes for psoriasis patients on biologics »
Related Articles
April 25, 2021
EHRA practical guide on cardiac imaging in electrophysiology
November 20, 2023
November 18, 2023
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com